Bloomberg TV and other stations “To Be Announced.”
Mr. James Sapirstein, Chairman & CEO of AzurRx BioPharma (NASDAQ: AZRX) talks to the “New To The Street’s” TV audience about AZRX’s biopharmaceutical products and therapies. He gives a comprehensive overview in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. And, provides insight on its FDA Phase 2 clinical trials on its lead therapeutic candidate MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis.
James Sapirstein, CEO, AZRX states, “I am excited to be a guest on the
‘New To The Street’ TV program. The show has had a tremendous track record; I am happy to join the ranks. I look forward to educating viewers about AzurRx BioPharma - about our business, our biopharmaceutical products and therapies, and our future to grow the Company.”